Cargando…

The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets

PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Saurabh, Kumar, Scherzer, Michael T., Shah, Parag P., Mims, Alice S., Lockwood, William W., Kraft, Andrew S., Beverly, Levi J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226700/
https://www.ncbi.nlm.nih.gov/pubmed/25238262
_version_ 1782343663758606336
author Saurabh, Kumar
Scherzer, Michael T.
Shah, Parag P.
Mims, Alice S.
Lockwood, William W.
Kraft, Andrew S.
Beverly, Levi J.
author_facet Saurabh, Kumar
Scherzer, Michael T.
Shah, Parag P.
Mims, Alice S.
Lockwood, William W.
Kraft, Andrew S.
Beverly, Levi J.
author_sort Saurabh, Kumar
collection PubMed
description PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in tumorigenesis, much less is known about PIM2 and PIM3. Therefore, in this study we have used in vitro cell culture models and in vivo bone marrow infection/transplantation to assess the comparative signaling and oncogenic potential of each of the three PIM kinases. All three PIM kinases were able to protect FL5.12 cells from IL-3 withdrawal induced death. Interestingly, the downstream signaling cascades were indistinguishable between the three kinases. Transplantation of murine bone marrow co-expressing MYC and PIM1, PIM2 or PIM3 caused rapid and uniformly lethal myeloid leukemia. De-induction of MYC 18 days following transplantation significantly increased the survival of mice, even with continual expression of PIM kinases. Alternatively, mice treated at the pre-leukemic stage with a PIM kinase inhibitor increased the lifespan of the mice, even with continual expression of the MYC transgene. These data demonstrate the role of PIM kinases in driving myeloid leukemia, and as candidate molecules for therapy against human malignancies.
format Online
Article
Text
id pubmed-4226700
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-42267002014-11-17 The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets Saurabh, Kumar Scherzer, Michael T. Shah, Parag P. Mims, Alice S. Lockwood, William W. Kraft, Andrew S. Beverly, Levi J. Oncotarget Research Paper PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in tumorigenesis, much less is known about PIM2 and PIM3. Therefore, in this study we have used in vitro cell culture models and in vivo bone marrow infection/transplantation to assess the comparative signaling and oncogenic potential of each of the three PIM kinases. All three PIM kinases were able to protect FL5.12 cells from IL-3 withdrawal induced death. Interestingly, the downstream signaling cascades were indistinguishable between the three kinases. Transplantation of murine bone marrow co-expressing MYC and PIM1, PIM2 or PIM3 caused rapid and uniformly lethal myeloid leukemia. De-induction of MYC 18 days following transplantation significantly increased the survival of mice, even with continual expression of PIM kinases. Alternatively, mice treated at the pre-leukemic stage with a PIM kinase inhibitor increased the lifespan of the mice, even with continual expression of the MYC transgene. These data demonstrate the role of PIM kinases in driving myeloid leukemia, and as candidate molecules for therapy against human malignancies. Impact Journals LLC 2014-08-13 /pmc/articles/PMC4226700/ /pubmed/25238262 Text en Copyright: © 2014 Saurabh et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Saurabh, Kumar
Scherzer, Michael T.
Shah, Parag P.
Mims, Alice S.
Lockwood, William W.
Kraft, Andrew S.
Beverly, Levi J.
The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
title The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
title_full The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
title_fullStr The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
title_full_unstemmed The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
title_short The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
title_sort pim family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226700/
https://www.ncbi.nlm.nih.gov/pubmed/25238262
work_keys_str_mv AT saurabhkumar thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT scherzermichaelt thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT shahparagp thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT mimsalices thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT lockwoodwilliamw thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT kraftandrews thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT beverlylevij thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT saurabhkumar pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT scherzermichaelt pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT shahparagp pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT mimsalices pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT lockwoodwilliamw pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT kraftandrews pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets
AT beverlylevij pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets